Focused On-demand Library for 5-hydroxytryptamine receptor 4

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We employ our advanced, specialised process to create targeted libraries for receptors.

 Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

Serotonin receptor 4

Alternative UPACC:

Q13639; C4WYH4; Q546Q1; Q684M0; Q712M9; Q96KH9; Q96KI0; Q9H199; Q9NY73; Q9UBM6; Q9UBT4; Q9UE22; Q9UE23; Q9UQR6


The 5-hydroxytryptamine receptor 4, also known as the Serotonin receptor 4, plays a pivotal role in neurotransmission and hormonal regulation. It is activated by serotonin, a key neurotransmitter and hormone involved in mood, appetite, and sleep. The receptor's activity is mediated by G proteins that stimulate adenylate cyclase, highlighting its importance in cellular signaling pathways.

Therapeutic significance:

Understanding the role of 5-hydroxytryptamine receptor 4 could open doors to potential therapeutic strategies. Its involvement in critical neurotransmitter and hormonal pathways makes it a promising target for treating disorders related to mood, appetite, and sleep regulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.